Npt2b deletion attenuates hyperphosphatemia associated with CKD

Journal of the American Society of Nephrology

Volumn 23, Issue 10, 2012, Pages 1691-1700

  Schiavi, Susan C ^a   Tang, Wen ^a   Bracken, Christina ^a   O'Brien, Stephen P ^a   Song, Wenping ^a   Boulanger, Joseph ^a   Ryan, Susan ^a   Phillips, Lucy ^a   Liu, Shiguang ^a   Arbeeny, Cynthia ^a   Ledbetter, Steven ^a   Sabbagh, Yves ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; SEVELAMER CARBONATE; SODIUM PHOSPHATE COTRANSPORTER 2B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BLOOD SAMPLING; BONE MINERAL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; GENE DELETION; HYPERPHOSPHATEMIA; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLAST; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN METABOLISM; RENAL OSTEODYSTROPHY; SERUM; UREMIA; URINALYSIS; WILD TYPE;

EID: 84867184149     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011121213     Document Type: Article

References (44)

1. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Sr, Gaziano JM, Vasan RS: Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 167: 879-885, 2007 (Pubitemid 46762749)
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
3. Cramer CF: Progress and rate of absorption of radiophosphorus through the intestinal tract of rats. Can J Biochem Physiol 39: 499-503, 1961
4. Kayne LH, D' Argenio DZ, Meyer JH, Hu MS, Jamgotchian N, Lee DB: Analysis of segmental phosphate absorption in intact rats. A compartmental analysis approach. J Clin Invest 91: 915-922, 1993 (Pubitemid 23095266)
5. McHardy GJR, Parsons DS: The absorption of inorganic phosphate from the small intestine of the rat. Q J Exp Physiol 41: 398-409, 1956
6. Sabbagh Y, O'Brien SP, Song W, Boulanger JH, Stockmann A, Arbeeny C, Schiavi SC: Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 20: 2348-2358, 2009
7. Sampathkumar K, Sooraj YS, Ajeshkumar RP: Extended release nicotinic acid is a promising agent for phosphate control in hemodialysis. Kidney Int 69: 1281, 2006
8. Musso CG, Reynaldi MJ, Aparicio C, Frydenlund S, Imperiali N, Algranati L: Hyperphosphatemia and nicotinic acid in peritoneal dialysis patients. Int Urol Nephrol 40: 229-230, author reply 231, 2008
9. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, Ebihara I, Koide H: Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 65: 1099-1104, 2004 (Pubitemid 38251086)
10. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW: A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 3: 1131-1138, 2008
11. Katai K, Tanaka H, Tatsumi S, Fukunaga Y, Genjida K, Morita K, Kuboyama N, Suzuki T, Akiba T, Miyamoto K, Takeda E: Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 14: 1195-1201, 1999 (Pubitemid 29209307)
12. Eto N, Miyata Y, Ohno H, Yamashita T: Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 20: 1378-1384, 2005 (Pubitemid 41430611)
13. Caldas YA, Giral H, Cortázar MA, Sutherland E, Okamura K, Blaine J, Sorribas V, Koepsell H, Levi M: Liver X receptor-activating ligands modulate renal and intestinal sodium-phosphate transporters. Kidney Int 80: 535-544, 2011
14. Cho KH, Kim HJ, Rodriguez-Iturbe B, Vaziri ND: Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure. Am J Physiol Renal Physiol 297: F106-F113, 2009
15. Ohi A, Hanabusa E, Ueda O, Segawa H, Horiba N, Kaneko I, Kuwahara S, Mukai T, Sasaki S, Tominaga R, Furutani J, Aranami F, Ohtomo S, Oikawa Y, Kawase Y, Wada NA, Tachibe T, Kakefuda M, Tateishi H, Matsumoto K, Tatsumi S, Kido S, Fukushima N, Jishage KI, Miyamoto KI: Inorganic phosphate homeostasis in sodium-dependent phosphate co-transporter Npt2b+/- mice. Am J Physiol Renal Physiol 301: F1105-F1113, 2011
16. Marks J, Churchill LJ, Srai SK, Biber J, Murer H, Jaeger P, Debnam ES, Unwin RJ; Epithelial Transport and Cell Biology Group: Intestinal phosphate absorption in amodel of chronic renal failure. Kidney Int 72: 166-173, 2007 (Pubitemid 47067387)
17. Moe SM, Radcliffe JS, White KE, Gattone VH 2nd, Seifert MF, Chen X, Aldridge B, Chen NX: The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. J Bone Miner Res 26: 2672-2681, 2011
18. Giral H, Caldas Y, Sutherland E, Wilson P, Breusegem S, Barry N, Blaine J, Jiang T, Wang XX, Levi M: Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate. Am J Physiol Renal Physiol 297: F1466-F1475, 2009
19. Hruska KA, Mathew S, Lund RJ, Memon I, Saab G: The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: The links between bone and the vasculature. Semin Nephrol 29: 156-165, 2009
20. Malluche HH, Mawad H, Monier-Faugere MC: The importance of bone health in end-stage renal disease: Out of the frying pan, into the fire? Nephrol Dial Transplant 19[Suppl 1]: i9-i13, 2004 (Pubitemid 38455637)
21. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G; Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953, 2006 (Pubitemid 43924257)
22. Lacour B, Lucas A, Auchère D, Ruellan N, de Serre Patey NM, Drüeke TB: Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 67: 1062-1069, 2005 (Pubitemid 41623331)
23. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-OM, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408, 2011
24. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M; HOST Investigators: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22: 1913-1922, 2011
25. Mirza MA, Larsson A, Lind L, Larsson TE: Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205: 385-390, 2009
26. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE: Serumintact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207: 546-551, 2009
27. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I: Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 22: 956-966, 2011
28. Parfitt AM: Renal bone disease: A new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 12: 387-403, 2003
29. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009
30. Felsenfeld A, Torres A: Bone histomorphometry in renal osteodystrophy. In: The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease, 2nd Ed., edited by Olgaard K, Silver J, Isidro B. Salusky IB, New York, Oxford University Press, 2010, 145-172
31. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46: 855-861, 1994 (Pubitemid 24272045)
32. Parfitt AM:Misconceptions (3): Calciumleaves bone only by resorption and enters only by formation. Bone 33: 259-263, 2003
33. Barreto DV, Barreto FC, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RM, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani ME: Phosphate binder impact on bone remodeling and coronary calcification - results from the BRiC study. Nephron Clin Pract 110: c273-c283, 2008
34. Ferreira A, Frazão JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH; Sevelamer Study Group: Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 19: 405-412, 2008
35. Sampath TK, Simic P, Moreno S, Bukanov N, Draca N, Kufner V, Tikvica A, Blair A, Semenski D, Brncic M, Burke SK, Vukicevic S: Sevelamer restores bone volume and improves bone microarchitecture and strength in aged ovariectomized rats. Endocrinology 149: 6092-6102, 2008
36. Koyama Y, Rittling SR, Tsuji K, Hino K, Salincarnboriboon R, Yano T, Taketani Y, Nifuji A, Denhardt DT, Noda M: Osteopontin deficiency suppresses high phosphate load-induced bone loss via specific modulation of osteoclasts. Endocrinology 147: 3040-3049, 2006 (Pubitemid 43764639)
37. Hayashibara T, Hiraga T, Sugita A, Wang L, Hata K, Ooshima T, Yoneda T: Regulation of osteoclast differentiation and function by phosphate: Potential role of osteoclasts in the skeletal abnormalities in hypophosphatemic conditions. J Bone Miner Res 22: 1743-1751, 2007 (Pubitemid 351235140)
38. Zhang R, Lu Y, Ye L, Yuan B, Yu S, Qin C, Xie Y, Gao T, Drezner MK, Bonewald LF, Feng JQ: Unique roles of phosphorus in endochondral bone formation and osteocytematuration. J Bone Miner Res 26: 1047-1056, 2011
39. Sabbagh Y, Graciolli FG, O'Brien S, Tang W, Dos Reis LM, Ryan S, Phillips L, Boulanger J, Song W, Bracken C, Liu S, Ledbetter S, Dechow P, Canziani ME, Carvalho AB, Jorgetti V, Moyses RM, Schiavi SC: Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 27: 1757-1772, 2012
40. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000 (Pubitemid 30318271)
41. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39: 695-701, 2002 (Pubitemid 34158168)
42. Westenfeld R, Schäfer C, Smeets R, Brandenburg VM, Floege J, Ketteler M, Jahnen-Dechent W: Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant 22: 1537-1546, 2007 (Pubitemid 47073751)
43. Gagnon RF, Duguid WP: A reproducible model for chronic renal failure in the mouse. Urol Res 11: 11-14, 1983 (Pubitemid 13093072)
44. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR; Report of the ASBMR Histomorphometry Nomenclature Committee: Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2: 595-610, 1987